Clinical controversies in the management of acute pulmonary embolism: evaluation of four important but controversial aspects of acute pulmonary embolism management that are still subject of debate and research.
Dieuwke LuijtenFrederikus Albertus KlokThijs E van MensMenno V HuismanPublished in: Expert review of respiratory medicine (2023)
Outside clinical trials, hemodynamically stable acute PE patients should not be treated with primary reperfusion therapy. Thrombolysis and/or catheter-directed therapy are only to be considered as rescue treatment. Subsegmental PE can be left untreated in selected low-risk patients, after proximal deep vein thrombosis has been ruled out. Patients with an sPESI or Hestia score of 0 criteria can be treated at home, independent of the presence of RV overload. Finally, health-care providers should be aware of post-PE syndrome and diagnose chronic thromboembolic pulmonary disease (CTEPD) as early as possible. Persistently symptomatic patients without CTEPD benefit from exercise training and cardiopulmonary rehabilitation.
Keyphrases
- pulmonary embolism
- end stage renal disease
- newly diagnosed
- healthcare
- chronic kidney disease
- ejection fraction
- clinical trial
- liver failure
- inferior vena cava
- prognostic factors
- stem cells
- randomized controlled trial
- heart failure
- hepatitis b virus
- drug induced
- mesenchymal stem cells
- percutaneous coronary intervention
- social media
- bone marrow
- cell therapy
- replacement therapy
- double blind
- placebo controlled